<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991051</url>
  </required_header>
  <id_info>
    <org_study_id>D0818R00007</org_study_id>
    <nct_id>NCT04991051</nct_id>
  </id_info>
  <brief_title>Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer</brief_title>
  <acronym>HALO</acronym>
  <official_title>HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is&#xD;
      essential to know the prevalence of HRD in women with advanced high-grade serous or&#xD;
      endometrioid ovarian cancer. Presently, the prevalence data for HRD are available from&#xD;
      selected geographies only and range from 31% to 50%. Furthermore, the risk factors associated&#xD;
      with HRD and clinical characteristics of patients with HRD need exploration for&#xD;
      region-specific differences. In the present study, we will estimate the region- and&#xD;
      country-specific prevalence of HRD in women with stage III or IV high-grade serous or&#xD;
      endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer and associated risk&#xD;
      factors with clinical characteristics in Asia-Pacific countries, Latin America, Africa,&#xD;
      Russia, Australia, and Middle East countries.&#xD;
&#xD;
      The findings of the study will help the oncologists in optimal patient selection and clinical&#xD;
      decision-making for the first-line maintenance of patients with HGSOC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cross-sectional, noninterventional, multicentre, epidemiological, observational study is&#xD;
      designed to determine the prevalence of HRD in patients with newly diagnosed high-grade&#xD;
      serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer. The study&#xD;
      will also determine the prevalence of tBRCA1m/tBRCA2m, genomic instability, and identify the&#xD;
      associated risk factors in several countries across broad geographic regions. The patients&#xD;
      with newly diagnosed high-grade (stage III or IV of Federation of Gynecology and Obstetrics&#xD;
      [FIGO] classification 2014, Prat J, 2015) ovarian cancer, having the availability of&#xD;
      formalin-fixed paraffin-embedded (FFPE) archival tumour tissue block(s) collected within past&#xD;
      120 days will be screened to enrol a minimum of 405 women after obtaining written informed&#xD;
      consent and eligibility assessment. The FFPE tumour tissue block(s) collected as part of&#xD;
      routine clinical care at public or private ovarian cancer management and or diagnostic&#xD;
      facilities in the selected countries will be sent for testing at Myriad Genetics laboratories&#xD;
      Inc.&#xD;
&#xD;
      at Salt Lake City, United States of America (USA) through Myriad's local logistics network.&#xD;
&#xD;
      This study will have a single visit.&#xD;
&#xD;
      The study centres and the respective investigators will be selected through a site-level&#xD;
      feasibility process after assessing the following:&#xD;
&#xD;
        -  availability of the average number patients with newly diagnosed stage III and IV serous&#xD;
           or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer.&#xD;
&#xD;
        -  completeness of patient medical records pertaining to diagnostics and having the&#xD;
           facility, capacity, and competence of collecting and archiving FFPE tumour tissue&#xD;
           block(s).&#xD;
&#xD;
      Assessment and selection of study centres by the study sponsor AstraZeneca (AZ) will be an&#xD;
      ongoing process during the entire course of the study until completion of recruitment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The overall percentage of patients diagnosed with positive HRD status</measure>
    <time_frame>Baseline</time_frame>
    <description>At baseline of this study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Region- and country-specific percentages of patients with positive HRD status</measure>
    <time_frame>Baseline</time_frame>
    <description>At baseline of this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall, region- and country-specific percentages of patients with tBRCA1m/tBRCA2m within each geographical region</measure>
    <time_frame>Baseline</time_frame>
    <description>At baseline of this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall, region- and country-specific percentages of patients with GIS-positive status within each geographical region</measure>
    <time_frame>Baseline</time_frame>
    <description>At baseline of this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of HRD-positive status and tBRCA1m/tBRCA2m</measure>
    <time_frame>Baseline</time_frame>
    <description>At baseline of this study</description>
  </secondary_outcome>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women with high-grade (stage III or IV of FIGO classification 2014) ovarian cancer will be&#xD;
        eligible for inclusion into the study if they meet all of the inclusion criteria and none&#xD;
        of the exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients â‰¥18 years of age or adults according to age of majority as defined by the&#xD;
             local regulations;&#xD;
&#xD;
          -  Willing and able to provide written informed consent for participation in the study;&#xD;
&#xD;
          -  Patients with histologically confirmed new diagnosis (within past 120 days of&#xD;
             enrolment) of high-grade (stage III or IV of FIGO classification 2014) serous or&#xD;
             endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer;&#xD;
&#xD;
          -  Patients having availability of histopathology report and FFPE archival tumour tissue&#xD;
             block(s) collected within past 120 days of enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with mucinous, clear-cell, undifferentiated carcinoma or malignant Brenner's&#xD;
             tumour;&#xD;
&#xD;
          -  Patients diagnosed with any severe acute or chronic medical or psychiatric conditions&#xD;
             that may increase the risk associated with study participation or may interfere with&#xD;
             the interpretation of the study results, and those in the judgment of the investigator&#xD;
             are not appropriate for enrolment in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luxor</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander Sultanbaev</last_name>
      <phone>+7 (347) 216-3671</phone>
      <email>info@onkorb.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istra Settlement</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valeria Saevets</last_name>
      <phone>8 (351) 214-88-88</phone>
      <email>lalili2013@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Kuzmenko</last_name>
      <phone>+7 (3452) 27-07-16</phone>
      <email>maria.72.tmn@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yuzhno-Sakhalinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer, HRD-testing, ovarian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

